Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

Protagenic Therapeutics reports sharply improved EPS for Q4 2025

Protagenic Therapeutics released results for the quarter ended 31.12.2025 and reported earnings per share (EPS) of 1.14 USD. In the same quarter a year earlier EPS was -3.360 USD, so the company recorded a marked improvement. » More on finanzen.net
Protagenic Therapeutics appoints William Nichols Jr. as president

Protagenic Therapeutics has appointed William (Bill) Nichols Jr., effective February 3, 2026, as president. Nichols (51) joins from senior commercial roles at bluebird bio, Dova Pharmaceuticals and Bristol-Myers Squibb. His contract provides a base salary of USD 350,000, an annual target bonus of 40% and stock options amounting to about 1.0% of the fully diluted shares. » More on de.investing.com
Protagenic Therapeutics reports quarterly loss of $0.47 per share

Protagenic Therapeutics published on 26.11.2025 the figures for the quarter ended 30.09.2025 and reported a loss per share of $0.47. In the same quarter last year, earnings per share were -$1.96. No further financial details were reported. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2005, Protagenic Therapeutics Aktie has already paid €407,058,437.54 in dividends. The last payout was in December 2005.

Financials

In the last quarter, Protagenic Therapeutics Aktie had revenue of €0 and net profit of -€844.33K

(EUR)	Jun 2026	YoY
Revenue	0	-
Gross profit	-7.28K	31.71%
Net profit	-844.33K	80.32%
EBITDA	-834.97K	79.52%

Fundamentals

Metric	Value
Market capitalization	€1.53M
Number of shares	1.81M
52-week high/low	€3.93 - €0.11
Dividends	No
Beta	1.07
P/E ratio	0.33
PEG ratio	0.00
P/B ratio	1.03
P/S ratio	0.00

Company profile

Protagenic Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Entdeckung und Entwicklung von Therapeutika zur Behandlung stressbedingter neuropsychiatrischer und stimmungsbezogener Störungen befasst. Die Leitsubstanz ist PT00114, eine synthetische Form von Teneurin carboxy-terminal associated peptide, einem endogenen Signalpeptid des Gehirns, das überaktive Stressreaktionen dämpfen kann. Das Unternehmen hat seinen Sitz in New York, New York.

Name	Protagenic Therapeutics Aktie
CEO	Garo H. Armen
Headquarters	Santa Barbara, ca USA
Website	protagenic.com
Sector	Industrials
Industry	Commercial Services & Supplies
IPO	04/27/2021
Employees	2